Global Targeted Drugs for Allergic Diseases Market Insights, Forecast to 2030

Global Targeted Drugs for Allergic Diseases Market Insights, Forecast to 2030

The global Targeted Drugs for Allergic Diseases market is projected to grow from US$ 37,149.12 million in 2024 to US$ 91,069.96 million by 2030, at a Compound Annual Growth Rate (CAGR) of 16.12% during the forecast period.

The US & Canada market for Targeted Drugs for Allergic Diseases is estimated to increase from $ 24,817.98 million in 2024 to reach $ 47,449.29 million by 2030, at a CAGR of 11.41% during the forecast period of 2025 through 2030.

The China market for Targeted Drugs for Allergic Diseases is estimated to increase from $ 2,303.36 million in 2024 to reach $ 16,524.16 million by 2030, at a CAGR of 38.88% during the forecast period of 2025 through 2030.

The Europe market for Targeted Drugs for Allergic Diseases is estimated to increase from $ 6,593.13 million in 2024 to reach $ 15,704.86 million by 2030, at a CAGR of 15.56% during the forecast period of 2025 through 2030.

The global key companies of Targeted Drugs for Allergic Diseases include Sanofi, AbbVie, Novartis, Incyte, Roche, AstraZeneca, GSK, Eli Lilly and Company, Amgen, Pfizer, Leo Pharma, Teva, Otsuka Pharmaceutical, Mabpharm etc. In 2023, the global top five players had a share approximately 75.25 % in terms of revenue.

Report Includes

This report presents an overview of global market for Targeted Drugs for Allergic Diseases market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Targeted Drugs for Allergic Diseases, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Targeted Drugs for Allergic Diseases, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Targeted Drugs for Allergic Diseases revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Targeted Drugs for Allergic Diseases market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Targeted Drugs for Allergic Diseases revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Sanofi, Novartis, GSK, Amgen, AstraZeneca, Pfizer, TEVA, Otsuka Pharmaceutical, and Roche, etc.

Market Segmentation

By Company

Sanofi

AbbVie

Novartis

Incyte

Roche

AstraZeneca

GSK

Eli Lilly and Company

Amgen

Pfizer

Leo Pharma

Teva

Otsuka Pharmaceutical

Mabpharm

Keymed Biosciences

Genrix Bio

Dragon Boat Pharmaceutical

Jiangsu Hengrui Pharmaceuticals

Sunshine Guojian

Qyuns Therapeutics

Biosion

Segment by Type

IL-4R

TSLP

IL-5

JAK

IgE

IL-13

Others

Segment by Application

Atopic Dermatitis

Asthma

Chronic Sinusitis with Nasal Polyps

Chronic Obstructive Pulmonary Disease

Others

By Region

North America

United States

Canada

China

Asia (excluding China)

Japan

South Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Russia

Italy

Other

Latin America

Brazil

Mexico

Argentina

Colombia

Other

Middle East & Africa

Saudi Arabia

UAE

Turkey

Other

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Revenue of Targeted Drugs for Allergic Diseases in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Targeted Drugs for Allergic Diseases companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.

Chapter 7: Europe by Type, by Application and by country, revenue for each segment.

Chapter 8: China by Type, and by Application, revenue for each segment.

Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.

Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.

Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Targeted Drugs for Allergic Diseases revenue, gross margin, and recent development, etc.

Chapter 12: Analyst's Viewpoints/Conclusions